Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Each COA includes third-party HPLC purity chromatograms, Mass Spectrometry structural identity validation, and quantitative LAL endotoxin testing results
N Engl J Med 1993;329:14:977-86
A single exposure (A) causes a small decrease (less than 3% of normal), in both blood and cytosolic GSH and Cys concentrations, with levels returning to above 99% of normal for all species within the simulated time-span
Tecentriq (atezolizumab) Disease area(s): Oncology Manufacturer(s): Roche 2024 Sales (USD): $4.13 billion Why it sold so well: In 2024, Roches cancer immunotherapy Tecentriq posted global sales of CHF 3.64 billion ($4.13 billion) and was the companys fourth best-selling drug after MS drug Ocrevus, hemophilia treatment Hemlibra and eye drug Vabysmo
US$ 20.66
US$ 23.06
US$ 26.93
